

Evaluation Report for Category L, Subcategory 1.1 Application

Application Number: 2022-2094
Application: Application subject to Protection of Proprietary Interests in Pesticide Data (PIIP) Policy – Equivalency/Data Compensation Assessment
Product: Sulfentrazone Agrogill Technical Grade Active Ingredient
Registration Number: 35137
Active ingredient (a.i.): Sulfentrazone
PMRA Document Number: 3543913

Purpose of Application

The purpose of this application was to register Sulfentrazone Agrogill Technical Grade Active Ingredient, a new source of the active ingredient sulfentrazone, based on a registered precedent product.

Chemistry Assessment

Common Name: Sulfentrazone
 IUPAC* Chemical Name: 2',4'-dichloro-5'-[4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]methanesulfonamide
 CAS† Chemical Name: N-[2,4-dichloro-5-[4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]phenyl]methanesulfonamide

* International Union of Pure and Applied Chemistry

† Chemical Abstracts Service

Sulfentrazone Agrogill Technical Grade Active Ingredient has the following properties:

Property	Result
Colour and physical state	Off-white solid
Nominal concentration	96.7%
Odour	Odourless
Density	1.3733 – 1.3792 g/mL at 20°C
Vapour pressure	1.98×10^{-2} mPa at 20°C
pH	5.75
Solubility in water	0.4 g/L (pH 6.92)
n-Octanol/water partition coefficient	$\log K_{ow} = 1.43$

The required chemistry data for Sulfentrazone Agrogill Technical Grade Active Ingredient have been provided, reviewed, and found to be acceptable.

Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of Sulfentrazone Agrogill Technical Grade Active Ingredient.

References

PMRA Document Number	Reference
3356226	2022, DACO 2.11.1 Summary of Manufacturing Process, DACO: 2.11.1 CBI
3356227	2022, DACO 2.11.2 & DACO 2.11.3 Detailed Flow Process of Sulfentrazone Technical Manufacturing, DACO: 2.11.2,2.11.3 CBI
3356228	2022, DACO 2.11.2 & DACO 2.11.3 Detailed Step Wise Manufacturing of Sulfentrazone Technical, DACO: 2.11.2,2.11.3 CBI
3356229	2022, DACO 2.11.4 Discussion of the Formation of Impurities Sulfentrazone, DACO: 2.11.4 CBI
3356240	2017, Physical and Chemical Characterization of Sulfentrazone TGAI - Color, Physical State, Odor, Stability to Normal and Elevated Temperature, Metals and Metal Ions, Storage Stability, Corrosive Characteristics, Oxidation/Reduction: Chemical Incompatibility, pH, UV/Vis Absorption, Melting Point, Density, Partition Coefficient, Solubility and Vapor Pressure, DACO: 2.14.1,2.14.11,2.14.12,2.14.13,2.14.15,2.14.2,2.14.3,2.14.4,2.14.6, 2.14.7,2.14.8,2.14.9, 830.7000 CBI
3356241	2017, Physical and Chemical Characterization of Sulfentrazone TGAI - Color, Physical State, Odor, Stability to Normal and Elevated Temperature, Metals and Metal Ions, Storage Stability, Corrosive Characteristics, Oxidation/Reduction: Chemical Incompatibility, pH, UV/Vis Absorption, Melting Point, Density, Partition Coefficient, Solubility and Vapor Pressure, DACO: 2.14.1,2.14.11,2.14.12,2.14.13,2.14.15,2.14.2,2.14.3,2.14.4,2.14.6, 2.14.7,2.14.8,2.14.9, 830.7000 CBI
3430780	2023, DACO 2.13.3 Batch Data Clarification for Submission 2022-2094, DACO: 2.13.3 CBI
3430781	2023, 22362 Sulfentrazone Technical Rep Final 28.01.2023, DACO: 2.13.4 CBI
3499322	2023, Chemical Composition of Five Batches of Sulfentrazone Technical Preliminary Analysis and Enforcement Analytical Methods for Sulfentrazone TGAI: Fulfilling the Requirements of OPPTS Guidelines 830.1700 and 830.1800 and EU Commission Regulation No., 283/2013, DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3499323	2023, DACO 2.13.4. Impurities of Human Health or Environmental Concern, DACO: 2.13.4 CBI
3537126	2023, Query - Study 23191 Sulfentrazone Technical 18.12.2023, DACO: 2.13.1 CBI

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.